Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions.

Two-thirds of Americans report spring allergies, and about 4 in 10 say they take an allergy medication several times a week. ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods ...

The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

SAN DIEGO — Approximately 45,000 patients have begun using omalizumab for food allergy in the year since its approval by the FDA, Ahmar Iqbal, MD, therapeutic area lead for respiratory and ...

Xolair (omalizumab) is a prescription drug that works by blocking IgE to help reduce inflammation. Your response to this drug may vary based on your medical history and diagnosis. IgE is a protein ...

JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

New treatment options are revolutionizing ways to manage and reduce the effects of food allergy. Biologics - medications that ...

In vitro, omalizumab and human IgE form several immune complexes that vary in size as the 2 components' molar ratios are changed. [29] The largest complex, a stable cyclical hexameric structure ...